Hyogo, Japan

Masamoto Fukasawa

This inventor holds 1 USPTO granted patent. Top assignee: Sumitomo Pharmaceuticals Company Limited. Active years: 1990.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Masamoto Fukasawa. Retrieved from https://idiyas.com/inventor/masamoto-fukasawa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 21(Granted Patents)


Company Filing History:


Years Active: 1990

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Masamoto Fukasawa

Introduction

Masamoto Fukasawa is a notable inventor based in Hyogo, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of carbapenem compounds. His work has implications for antibiotic development and treatment options.

Latest Patents

Fukasawa holds a patent for "Carbapenem compounds and production thereof." This patent describes a compound with a specific formula, where R₁ can be a hydrogen atom or a lower alkyl group, and R₂ can be a hydrogen atom or a conventional protecting group for a carboxyl group. The patent details various chemical groups and their configurations, showcasing Fukasawa's expertise in organic chemistry.

Career Highlights

Fukasawa is associated with Sumitomo Pharmaceuticals Company Limited, where he has been instrumental in advancing pharmaceutical research. His innovative approach to drug development has positioned him as a key figure in the industry.

Collaborations

Fukasawa has worked alongside talented colleagues such as Makoto Sunagawa and Haruki Matsumura. Their collaborative efforts have contributed to the success of various projects within the company.

Conclusion

Masamoto Fukasawa's contributions to the field of pharmaceuticals through his innovative patents and collaborations highlight his importance as an inventor. His work continues to influence the development of new therapeutic compounds.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…